Clinigen Group Plc (NASDAQ:CLIGF) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Zacks has also assigned Clinigen Group Plc an industry rank of 101 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research cut Clinigen Group Plc from a “buy” rating to a “hold” rating in a report on Wednesday, May 24th.

TRADEMARK VIOLATION NOTICE: “Zacks: Clinigen Group Plc (CLIGF) Given Average Recommendation of “Strong Buy” by Analysts” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at

Clinigen Group Plc (NASDAQ CLIGF) remained flat at $13.90 on Friday. Clinigen Group Plc has a 1-year low of $8.70 and a 1-year high of $13.90. The company has a market capitalization of $1.60 billion and a P/E ratio of 85.28.

Get a free copy of the Zacks research report on Clinigen Group Plc (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.